With regard to the INCB054329 inhibitor and its potential to downregulate IL6R expression and sensitize myeloma cells to JAK2 inhibitors, preclinical studies combining this compound with inhibitors of the JAK-STAT pathway such as ruxolitinib or itacitinib demonstrated synergistic effects and enhanced efficiency in reducing myeloma cell proliferation and MM tumor growth [82]. The gene discussed is JAK2; the disease is plasma cell myeloma.